Login to Your Account



Up to $145M in Milestones Per Program

Evotec, J&J Dig Deeper into AD: Deal Seeking Molecular Triggers

By Randy Osborne
Staff Writer

Friday, November 8, 2013
The Johnson & Johnson (J&J) Innovation Center, through J&J unit Janssen Pharmaceuticals Inc., is pledging up to $10 million up front per program, followed by as much as $145 million more for each, in a deal with Evotec AG that aims to find and target the true originators of Alzheimer’s disease (AD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription